Celltrion said on the 7th that Truxima, a blood cancer treatment, ranked No. 1 in U.S. prescription share. Truxima is a biosimilar of Rituxan, sold by Switzerland's Roche, and was launched in the United States in Nov. 2019.
Truxima is the first biosimilar from Korea to rank No. 1 in U.S. prescription share. According to IQVIA, Truxima posted a 35.8% share in the United States in Feb. this year. Truxima generated more than 300 billion won in sales in North America, including the United States, last year.
The autoimmune disease treatments Inflectra and Steqeyma recorded 30.5% and 10.2% market shares, respectively, in the United States. The company plans to launch Abtozma in a subcutaneous injection formulation and OMLYCLO in the United States in the second half of this year. Abtozma is an autoimmune disease treatment that is currently in an intravenous injection formulation. OMLYCLO is an allergy treatment.
A Celltrion official said the company "proved the potential of Korea's bio and pharmaceutical corporations to enter the U.S. market," adding that "sales of existing flagship products are stable, and newly launched high-margin products are also increasing their shares."